medicalmeds.eu Medicines The means operating on a nervous system. A Vinpocetine - Darnitsa, the tab. 0,005 No. 30

Vinpocetine - Darnitsa, the tab. 0,005 No. 30

Препарат Винпоцетин - Дарница, табл. 0,005 №30. ЗАО "Фармацевтическая фирма "Дарница" Украина

Producer: CJSC Pharmaceutical Firm Darnitsa Ukraine

Code of automatic telephone exchange: N06B X18

Release form: Firm dosage forms. Tablets.

Indications to use: Disturbance of cerebral circulation. Atherosclerosis of vessels of a brain. Menyer's disease. Senile relative deafness.

General characteristics. Structure:

active ingredient: vinpocetine; 1 tablet contains a Vinpocetine in terms of 100% dry matter of 5 mg;

excipients: lactoses monohydrate, potato starch, magnesium stearate.

Pharmacological properties:

Pharmacodynamics. The Vazodilatiruyushchy means improving cerebral circulation. Causes small decrease in system arterial pressure, brain vasodilatation, strengthening of a blood-groove and improvement of supply of a brain with oxygen and glucose. Increases resistance of cells of a brain to a hypoxia, facilitating transport of oxygen and substrates of power providing to fabrics (strengthening of absorption and metabolism of glucose, its switching to energetically more favorable aerobic direction). Promotes accumulation in tsAMF and ATP fabrics (braking of phosphodiesterase (FDE) and stimulation of adenylatecyclase), increase in maintenance of catecholamines in brain tissues.

Vazodilatiruyushchy action is connected with the direct running-down impact on smooth muscles of vessels preferential of a brain. The Vinpocetine does not cause a phenomenon of "burglarizing", first of all strengthens blood supply of ischemic area of a brain, without changing at the same time blood supply of intact sites. Improves microcirculation in a brain due to reduction of aggregation of thrombocytes, decrease in viscosity of blood, increase in deformability of erythrocytes.

Pharmacokinetics. At intake it is quickly and completely absorbed in digestive tract. Bioavailability – 50–70%. Time of achievement of the maximum concentration in a blood plasma (TCmax) – 1 h. The maximum concentration in plasma – 10– 20 ng/ml. An elimination half-life (T1/2) – 4,74–5 h. Easily gets through gistogematichesky barriers including hematoencephalic.

Indications to use:

Insufficiency of cerebral circulation which is followed by neurologic and mental disturbances: a state after a stroke, vertebro-basilar insufficiency, cerebral atherosclerosis, vascular dementia, encephalopathy (hypertensive, posttraumatic).

Vascular diseases of eyes (chronic vascular diseases of a choroid and retina of an eye).

Decrease in auditory acuity of vascular or toxic genesis, senile relative deafness, Menyer's disease, ring in ears.

Route of administration and doses:

Vinpotsetin-Darnitsa accept inside before the use of food.

Appoint the adult 5 mg (1 tablet) 3 times a day. Treatment duration – 2 months. If necessary repeated courses can be appointed (2–3 times a year).

Features of use:

Drug with care is appointed the patient with arrhythmias and stenocardia.

In the presence of a syndrome of the extended interval of QT or at simultaneous use of the drugs provoking lengthening of an interval of QT control of an ECG is necessary.

Drug contains lactose.

Use during pregnancy or feeding by a breast. Drug is contraindicated during pregnancy and feeding by a breast.

Children. Adequate and strictly controlled researches on safety and efficiency of drug for children were not conducted. There is no objective experience of use of drug for children.

Ability to influence the speed of reactions at control of motor transport or other mechanisms. During treatment driving of motor transport and occupation is forbidden by other potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions.

Side effects:

From cardiovascular system: (0,1%) ST depression, lengthening of an interval of QT, tachycardia, premature ventricular contraction, however existence of a causal relationship between side effects and treatment by the Vinpocetine is not proved since in natural population these symptoms are observed with the same frequency; 0,8%: change of arterial pressure (decrease is more often), erubescence.

From the central nervous system: (0,9%) a sleep disorder (sleeplessness, the increased drowsiness), dizziness, a headache, the general weakness (symptoms can be manifestations of a basic disease).

From system of digestion: (0,6%) nausea, heartburn, dryness in a mouth.

From immune system: (0,2%) allergic reactions.

Interaction with other medicines:

At simultaneous use of Vinpotsetin-Darnits and heparin the risk of hemorrhagic complications increases.

Contraindications:

Hypersensitivity to drug components. Heavy disturbances of a heart rhythm, the expressed obstruction of coronary arteries. Pregnancy, feeding period breast.